Astrid Zimmermann

University of Bern — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index2.3kcitations211works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

DNA Repair Mechanisms(47), DNA and Nucleic Acid Chemistry(39), Click Chemistry and Applications(28), Cancer therapeutics and mechanisms(23), Nuclear Receptors and Signaling(19)

Publications211 total

Supplementary Data from Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors
2025Open Access
Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
2025Open Access
Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
2025Open Access
Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
2025Open Access
Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
2025Open Access
Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
2025Open Access
Abstract A031: DNA-PK reenforces the S/G2 checkpoint in ATM-deficient cells to limit ATR inhibitor efficacy
Molecular Cancer Therapeutics·2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the <scp>ATR</scp> Inhibitor Tuvusertib
Clinical Pharmacology & Therapeutics·2025· 1 citedOpen Access
Holocene climate and human impacts on vegetation dynamics in the Swiss Alps highlight biodiversity conservation challenges
The Holocene·2025· 1 cited
Abstract 1171: M9466 (HRS-1167): A highly potent and selective PARP1 inhibitor with DNA trapping activity, monotherapy antitumor activity and synergistic potential with DDR inhibitors and chemotherapies
Cancer Research·2025
DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of<sup>177</sup>Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma
Journal of Nuclear Medicine·2025· 4 citedOpen Access
Semi-mechanistic efficacy model for PARP + ATR inhibitors—application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs
British Journal of Cancer·2025· 3 citedOpen Access
PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells
Cell Death Discovery·2025· 7 citedOpen Access
Figure 4 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
2025Open Access
Supplementary Data from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
2025Open Access
Figure 1 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
2025Open Access
Supplementary Tables S1-S4 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
2025Open Access
Figure 3 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
2025Open Access
Data from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
2025Open Access
Figure 5 from Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors
2025Open Access
page 1 of 11Next →

Frequent Co-authors

Frank T. Zenke(18), Andree Blaukat(12), Heike Dahmen(11), Arne Sutter(7), Thomas Fuchß(6), Christian Sirrenberg(5), Jean A. Laissue(5), Yves Pommier(4), Ulrich Pehl(4), Thomas Grombacher(4), Mouming Zhao(4), Anish Thomas(3), Nobuyuki Takahashi(3), Christopher W. Schultz(3), Christiane Amendt(3), Eric M. Shooter(3), Li-Ya Chiu(3), Lyubomir T. Vassilev(3), Vinodh N. Rajapakse(2), Yang Zhang(2)